Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL

NCT01466153 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT01466153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01466153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Completed
Start date
February 7, 2012
Completion date
January 8, 2016
Enrollment
183 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia (cll)